Morphine-Equivalent Analgesia with Superior Safety Profile: At 0.3mg, Buprigesic delivers analgesia pharmacologically equivalent to 10mg morphine sulphate in adults, while the ceiling effect on respiratory depression at higher doses provides a clinically meaningful safety advantage over full mu-agonists in both human and veterinary applications.

Rapid Onset, Sustained Duration: Pharmacological effects commence within 15 minutes of intramuscular injection, with peak effects at approximately 1 hour and duration extending to 6 hours or longer reducing dosing frequency in clinical pain management settings.

Partial Agonist Lower Dependence Liability: Buprenorphine's partial agonism and characteristically slow receptor dissociation produce significantly lower manifest physical dependence compared to full opioid agonists, making it clinically advantageous for both pain management and dependence treatment.

Dual-Route Administration: Suitable for both deep intramuscular and slow intravenous administration, providing flexible delivery options across clinical and veterinary settings.

Opioid Dependence Management: Beyond analgesia, Buprigesic's partial agonist properties make it a pharmacologically rational intervention in opioid use disorder, reducing withdrawal severity and cravings while blocking the reinforcing effects of illicit opioid use.

Sterile, Precisely Dosed Ampoule Presentation: Available in sealed 1ml ampoules containing exactly 0.3mg Buprenorphine ensuring accurate, consistent dosing with each administration.

WHO-GMP Manufactured: Produced by Neon Laboratories Ltd. across manufacturing facilities compliant with World Health Organization Good Manufacturing Practice standards ensuring batch-to-batch consistency, sterility assurance, and pharmaceutical-grade quality throughout.

How to Use:

Buprigesic 0.3mg Injection must be administered by or under the direct supervision of a qualified medical or veterinary professional. It must not be self-administered. Inspect the ampoule visually for particulate matter or discolouration before use; do not administer if either is observed.

The dose, frequency, and duration of treatment must always be individually determined by the prescribing physician or veterinarian based on the patient's condition, weight, response to treatment, concurrent medications, and overall health status. Do not stop or alter the dosing schedule without professional guidance, as abrupt discontinuation may precipitate withdrawal symptoms in patients on regular therapy.

Storage Advice:

Store Buprigesic 0.3mg Injection ampoules in a cool, dry place below 25°C, away from direct sunlight and heat sources. Do not freeze. Handle ampoules with care to prevent breakage. Once opened, the entire contents of the ampoule must be used immediately partial-use ampoules must not be stored or reused, as this is a single-dose sterile unit. As a Schedule H / controlled substance, Buprigesic must be stored securely in accordance with applicable narcotics and controlled substances regulations under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. Keep out of reach of children. Do not use after the expiry date printed on the ampoule and outer carton.

About Neon Laboratories Ltd:

Neon Laboratories Ltd. is one of India's most respected and long-established pharmaceutical companies, incorporated in Mumbai in 1982 under the leadership of the Jain family and promoted by Mr. B.K. Jain, Chairman and Managing Director. Launching its first anaesthetic product in 1984, Neon rapidly grew from a focused parenteral anaesthesia manufacturer into a fully diversified pharmaceutical group with recognised leadership in anaesthesiology, critical care, pain management, oncology, cardiology, and gynaecology. With three WHO-GMP compliant manufacturing facilities including a primary facility at Palghar, Maharashtra Neon operates with an uncompromising commitment to Total Quality Management, manufacturing over 40 parenteral molecules with a basket of products that spans Active Pharmaceutical Ingredients, injectable formulations, transdermal delivery systems, and oral solid dosage forms. Holding more than 14 Indian and global patents and serving markets across India, the Middle East, Central America, and South America, Neon's four-decade track record of pharmaceutical innovation, quality-first culture, and rigorous regulatory compliance aligns deeply with Animeal's commitment to bringing only the most clinically credible and trusted products to India's pet parents and veterinary community. Discover Neon Laboratories today.

Disclaimer:

Please note that Buprigesic 0.3mg Injection (Buprenorphine Hydrochloride IP) is a Schedule H prescription-only pharmaceutical and a controlled substance regulated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. This product must not be purchased, possessed, or administered without a valid prescription issued by a registered medical practitioner or veterinarian. It must under no circumstances be self-administered by a patient or pet owner outside of a clinical or supervised veterinary setting. Buprenorphine carries a risk of opioid dependence, abuse, and misuse, which can lead to overdose and death if used outside of medically supervised protocols. The product information provided on this page is intended strictly for educational and informational reference purposes and does not constitute medical advice, veterinary advice, a diagnosis, or a treatment recommendation. All dosage, administration, and treatment decisions must be made exclusively by a qualified physician or veterinarian following individual clinical assessment. For animals, this product should only be administered by or under the direct supervision of a licensed veterinarian. Animeal supports your pet's health and wellbeing but does not replace the expertise or clinical judgement of a qualified veterinary professional.